Table 1 The correlation of RAC3 expression levels and clinical-pathological features in CRC
From: RAC3 influences the chemoresistance of colon cancer cells through autophagy and apoptosis inhibition
Variable | Number of patients | RAC3 expression (qPCR) | Fisher’s (P) | ||
|---|---|---|---|---|---|
< 1 | 10–100 | > 100 | |||
Normal tissue | 3a | 3 (100) | |||
Gender | 0.5055 | ||||
Male | 5 | 2 (40.0) | 2 (40.0) | 1 (20.0) | |
Female | 9 | 1 (11.0) | 6 (66.7) | 2 (22.2) | |
Differentiation | 0.5941 | ||||
Well | 1 | 0 (0) | 1 (100) | 0 (0) | |
Moderate | 11 | 3 (27.3) | 7 (63.6) | 1 (9.1) | |
Poor | 2 | 0 (0) | 0 (0) | 2 (100) | |
Tumor status | 0.4660 | ||||
T1 | 2 | 1 (50.0) | 1 (50.0) | 0 (0) | |
T2 | 0 | 0 (0) | 0 (0) | 0 (0) | |
T3 | 10 | 2 (20.0) | 6 (60.0) | 2 (20.0) | |
T4 | 2 | 0 (0) | 1 (50.0) | 1 (50.0) | |
Nodal status | 0.1280 | ||||
N0 | 9 | 3 (33.3) | 4 (44.4) | 2 (22.2) | |
N1–2 | 5 | 0 (0) | 4 (80.0) | 1 (20.0) | |
Metastasis status | 1.000 | ||||
M0 | 12 | 3 (25.0) | 6 (50.0) | 3 (25.0) | |
M1 | 2 | 0 (0) | 2 (100) | 0 (0) | |
Clinical stage | 0.1923 | ||||
I + II | 7 | 3 (42.9) | 4 (57.1) | 0 (0) | |
III + IV | 7 | 0 (0) | 4 (57.1) | 3 (42.9) | |